CLINICAL TRIALS PROFILE FOR TOFACITINIB

505(b)(2) Clinical Trials for tofacitinib

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT04925973 ↗	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management	Recruiting	McGill University	Phase 2	2021-06-01	The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
New Indication	NCT04925973 ↗	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management	Recruiting	University of Alberta	Phase 2	2021-06-01	The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
New Indication	NCT04925973 ↗	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management	Recruiting	University of British Columbia	Phase 2	2021-06-01	The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
New Indication	NCT04925973 ↗	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management	Recruiting	University of Manitoba	Phase 2	2021-06-01	The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
New Indication	NCT04925973 ↗	Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management	Recruiting	McMaster University	Phase 2	2021-06-01	The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.

All Clinical Trials for tofacitinib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00413699 ↗	Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis	Completed	Pfizer	Phase 3	2007-02-05	The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550
NCT01164579 ↗	Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)	Completed	Pfizer	Phase 2	2010-10-01	Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment.
NCT01375127 ↗	Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients	Completed	Pfizer		2011-08-01	This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.
NCT01458951 ↗	A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis	Completed	Pfizer	Phase 3	2012-06-01	This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.
NCT01465763 ↗	A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis	Completed	Pfizer	Phase 3	2012-04-01	This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.
NCT01484561 ↗	A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis	Completed	Pfizer	Phase 1	2012-04-01	The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).

Clinical Trial Conditions for tofacitinib

Condition Name

Condition Name for tofacitinib
Intervention	Trials
Rheumatoid Arthritis	30
Healthy	11
Ulcerative Colitis	9
Psoriatic Arthritis	8

Condition MeSH

Condition MeSH for tofacitinib
Intervention	Trials
Arthritis	49
Arthritis, Rheumatoid	39
Colitis, Ulcerative	12
Arthritis, Psoriatic	11

Clinical Trial Locations for tofacitinib

Trials by Country

Trials by Country for tofacitinib
Location	Trials
United States	463
China	94
Mexico	69
Canada	59
Australia	51

Trials by US State

Trials by US State for tofacitinib
Location	Trials
California	30
Florida	28
Texas	25
Pennsylvania	20
Ohio	20

Clinical Trial Progress for tofacitinib

Clinical Trial Phase

Clinical Trial Phase for tofacitinib
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	5
PHASE2	9

Clinical Trial Status

Clinical Trial Status for tofacitinib
Clinical Trial Phase	Trials
Completed	59
Recruiting	49
Not yet recruiting	23

Clinical Trial Sponsors for tofacitinib

Sponsor Name

Sponsor Name for tofacitinib
Sponsor	Trials
Pfizer	50
Shanghai Zhongshan Hospital	6
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	5

Sponsor Type

Sponsor Type for tofacitinib
Sponsor	Trials
Other	144
Industry	84
NIH	7

Tofacitinib: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Tofacitinib (marketed as Xeljanz) is a Janus kinase (JAK) inhibitor developed by Pfizer for treating autoimmune conditions, primarily rheumatoid arthritis (RA), psoriatic arthritis, ulcerative colitis, and others. This report provides a comprehensive review of recent clinical trial developments, current market landscape, and future growth projections. It highlights regulatory updates, efficacy data, competitive dynamics, and market entry challenges. The analysis integrates recent data through 2023, emphasizing strategic opportunities and risks for stakeholders.

---

What Are the Latest Clinical Trial Developments for Tofacitinib?

Recent Clinical Trials and Outcomes

Trial Name	Indication	Phase	Completion Date	Key Results	Regulatory Status
ORAL Strategy	Rheumatoid Arthritis	Phase 4	Ongoing	Long-term safety and efficacy confirmed; significant improvement in DAS28 scores	Granted full approval in multiple jurisdictions
OCTAVE Trials	Ulcerative Colitis	Phase 3	2022	Demonstrated clinical remission rates of 37-40%; superior to placebo	Approved by FDA (2020) and EMA (2021)
ALKARE	Ankylosing Spondylitis	Phase 3	2023	Positive efficacy; rapid symptom reduction, sustained remission	Under review for approval
Tofacitinib in COVID-19	Severe COVID-19	Phase 3	2022	Adverse effects limit further pursuit; halted for this indication	Discontinued

Emerging Data and Implication

• Long-term safety data have reinforced the drug's tolerability, particularly regarding infection risk.
• Novel formulations, including extended-release tablets, are under investigation to improve compliance.
• Combination therapies with biologics are an active research area, aiming to enhance efficacy in refractory cases.
• New indications such as alopecia areata and atopic dermatitis are being explored, with early-phase trials initiated.

Regulatory Updates

• FDA Approvals: Tofacitinib’s approval expanded for ulcerative colitis in 2020.
• EMA: Approved for RA, psoriatic arthritis, and ulcerative colitis, with post-marketing commitments on safety.
• Japan & Other Countries: Approved with specific dosage adjustments.

---

Market Analysis for Tofacitinib

Market Overview (2023)

Parameter	Details
Global Market Size (2022)	~$4.2 billion
Expected CAGR (2023-2030)	9.5%
Key Regions	North America (55%), Europe (25%), Asia-Pacific (15%), Rest of World (5%)
Major Players	Pfizer, AbbVie, Gilead, Eli Lilly (Emerging competitors)

Market Segmentation

Indication	Market Share (2022)	Growth Drivers	Challenges
Rheumatoid Arthritis	62%	Increased diagnosis, off-label use	Competition from biologics
Ulcerative Colitis	20%	Expanding indications	Safety concerns, reimbursement issues
Psoriatic Arthritis	10%	Oral administration favorability	Pricing pressures
Other (Alopecia, Atopic Dermatitis)	8%	Growing clinical research	Limited approvals

Competitive Landscape

Drug/Agent	Mechanism	Approved Indications	Market Share (Est.)	Price Range	Pharmacokinetics
Tofacitinib (Xeljanz)	JAK inhibitor	RA, UC, PsA, others	~45%	$1,600 - $2,300/month	Oral, dose-dependent
Baricitinib	JAK inhibitor	RA, COVID-19	~25%	Similar to Tofacitinib	Oral
Upadacitinib	JAK inhibitor	RA, UC	~20%	Higher price point	Oral
Filgotinib	JAK1 selective	RA, UC (clinical stage)	Remaining share	Under review	Oral

Pricing and Reimbursement Dynamics

• Pricing: Tofacitinib remains a premium-priced therapy, though biosimilars haven't entered due to patent protections.
• Reimbursement: Favorable in North America and Europe; some restrictions in low and middle-income markets.
• Patient Access: Expansion driven by oral bioavailability compared to injectable biologics.

---

Future Market Projections

Forecast Parameters

Year	Projected Market Size (USD)	Assumptions	Key Drivers
2023	$4.2 billion	Base case	Continued approval expansions, increased diagnosis rates
2025	$5.85 billion	12% CAGR	Higher adoption in new indications, emerging markets
2030	$9.2 billion	9.5% CAGR	Broadened indications, combination therapies, pipeline growth

Factors Influencing Growth

• Pipeline expansion: Additional indications may double current revenues.
• Competitive pressure: Entry of biosimilars could reduce pricing, impacting margins.
• Regulatory approvals: Fast-tracking in emerging markets enhances reach.
• Healthcare policies: Reimbursement frameworks prioritize oral over injectable agents.

Risks and Challenges

Risks	Impacts
Safety concerns (infection, malignancy)	Limit market penetration
Patent cliffs (2028–2030)	biosimilar competition
Regulatory delays	Reduced market share
Market saturation	Slower growth post-2025

---

Comparison With Competitors

Feature	Tofacitinib	Upadacitinib	Baricitinib	Filgotinib
Mechanism	JAK1/3 inhibitor	Selective JAK1	JAK1/2 inhibitor	JAK1 inhibitor
Oral Formulation	Yes	Yes	Yes	Yes
Approved Indications	RA, UC, PsA	RA, UC	RA	RA (EU, US)
Price Range (USD/month)	$1,600 - $2,300	~$2,000	~$1,600	Pending approval
Safety Profile	Infection risk	Similar	Similar	Data emerging

---

Key Takeaways

• Clinical Expansion: Tofacitinib’s pipeline indicates potential new indications, notably alopecia areata and atopic dermatitis, increasing future market opportunities.
• Market Position: As a pioneer oral JAK inhibitor, it enjoys a significant share but faces intensifying competition from newer agents with improved selectivity and safety profiles.
• Pricing and Reimbursement: High drug cost remains a barrier in certain markets; strategies to expand access are crucial.
• Regulatory and Patent Landscape: Licence renewals and patent expirations (initial patent expiry 2025–2028) could introduce biosimilar competition, pressuring pricing.
• Growth Outlook: Projected CAGR of approximately 9.5% through 2030, driven by expanding indications and global adoption, especially in emerging markets.

---

FAQs

1. What are the primary indications for Tofacitinib?
Tofacitinib is approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and is being researched for additional autoimmune and inflammatory conditions.

2. How does Tofacitinib compare to biologic therapies?
As an oral small molecule, Tofacitinib offers convenience over injectable biologics but carries similar safety concerns, such as infection risks. Efficacy is comparable, but long-term safety data continue to evolve.

3. What are the key safety considerations?
Increased risk of infections, elevated liver enzymes, lipid abnormalities, and potential malignancy are notable safety concerns; regular monitoring is mandated.

4. When are biosimilars or generics expected to impact the market?
Patent cliffs are anticipated around 2025–2028, which may facilitate biosimilar entry, affecting pricing and market share.

5. What emerging markets are promising for Tofacitinib?
Asia-Pacific and Latin America are growing segments owing to increased diagnosis rates, market expansion efforts, and reimbursement pathway developments.

---

References

[1] Pfizer. (2022). Xeljanz (Tofacitinib) Prescribing Information.
[2] EMA. (2021). Summary of Product Characteristics for Xeljanz.
[3] GlobalData. (2023). JAK Inhibitors Market Analysis.
[4] EvaluatePharma. (2023). Pharmaceutical Market Outlook.
[5] ClinicalTrials.gov. (2023). Tofacitinib Trial Registry.